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Abstract: Monitoring malaria prevalence in humans, as well as vector populations, for the presence
of Plasmodium, is an integral component of effective malaria control, and eventually, elimination.
In the field of human diagnostics, a major challenge is the ability to define, precisely, the causative
agent of fever, thereby differentiating among several candidate (also non-malaria) febrile diseases.
This requires genetic-based pathogen identification and multiplexed analysis, which, in combination,
are hardly provided by the current gold standard diagnostic tools. In the field of vectors, an
essential component of control programs is the detection of Plasmodium species within its mosquito
vectors, particularly in the salivary glands, where the infective sporozoites reside. In addition, the
identification of species composition and insecticide resistance alleles within vector populations is a
primary task in routine monitoring activities, aiming to support control efforts. In this context, the
use of converging diagnostics is highly desirable for providing comprehensive information, including
differential fever diagnosis in humans, and mosquito species composition, infection status, and
resistance to insecticides of vectors. Nevertheless, the two fields of human diagnostics and vector
control are rarely combined, both at the diagnostic and at the data management end, resulting in
fragmented data and mis- or non-communication between various stakeholders. To this direction,
molecular technologies, their integration in automated platforms, and the co-assessment of data
from multiple diagnostic sources through information and communication technologies are possible
pathways towards a unified human vector approach.
Keywords: diagnostics (Dx); epidemics; information and communication technologies (ICT);
insecticide resistance; malaria; One Health; vector-borne diseases
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1. Introduction
Malaria is one of the most widespread infectious diseases, both in terms of geographical distribution
and human cases. It is caused by a protozoan parasite of the species Plasmodium (P.) falciparum, P. vivax,
P. malariae, and P. ovale. Among these, P. falciparum and P. vivax are the most prevalent, and P. falciparum the
most pathogenic. P. knowlesi is a zoonotic malaria parasite that is known to spill over from its macaque
reservoir host and may cause disease in humans. Malaria is a vector-borne disease transmitted from
humans to humans through the bite of a female anopheline mosquito.
Despite the fact that malaria is a preventable and treatable disease, according to the World Health
Organization (WHO) World Malaria Report 2017, there were 216 million cases and 445,000 death cases
reported in 2016, with the African Region suffering approximately 90% of all malaria cases and deaths
worldwide [1]. In addition to the human losses, malaria in endemic countries is a heavy burden to the
healthcare systems, while it also inhibits socioeconomic development. The disease was considered as
endemic in 91 countries in 2016, reduced from 108 in 2000. Much progress has been done during the
past decade, with various malaria interventions leading to a 47% decline in malaria mortality rates
globally between 2001 and 2013; however, the challenge still exists.
Although the major geographic distribution of malaria is assumed around the equator, it keeps
being a latent global threat. Given the relation between malaria transmission and climate [2], the
increase in global temperature is possibly causing tropical diseases and vectors to spread to higher
altitudes in mountainous regions, and to higher latitudes that were previously spared. Furthermore,
recent outbreaks of malaria in countries that had been malaria-free indicate the continuous threat
of re-establishment of the disease in areas that were considered malaria-free [3]. The globalization
and increased transportation of people are important risk factors for the disease spreading towards
non-endemic regions [4,5]. Moreover, it is common in Europe and other high income countries to
travel abroad for business or leisure, and that increases the probability of infections spreading due to
returning travelers [6,7].
The challenges that prevent the rapid progress against malaria elimination are multi-factorial:
(i) systemic: lack of sustainable investments and funding, poor functionality of healthcare systems,
and unregulated environment are overall hurdles; (ii) biological: a major challenge presents with the
ever-increasing resistance of parasites to antimalarial medicines, and of mosquitoes to insecticides;
(iii) technical: lack of suitable tools to diagnose and treat efficiently, and lack of surveillance tools
for evaluation of changes in prevalence, or gaps in the monitoring systems. A significant source of
risk derives from patients infected with malaria parasites, but remain asymptomatic or undiagnosed.
This group of people is unintentionally acting as an infectious parasite reservoir and contributing
to the cycle of malaria transmission. Thus, for elimination, future diagnostic and treatment tools
and strategies must undoubtedly be able to identify and aim at this target group as well, so as to
clear malaria parasites from asymptomatic carriers. This will be strategically achieved through the
adaptability of health systems and available tools, to prevent, detect, and treat not only the clinical
cases, but every malaria infection, including the aforementioned asymptomatic ones.
Within this global landscape, the goals of the Global Technical Strategy for Malaria 2016–2030 [8]
towards malaria elimination are built around three pillars: (1) ensure universal access to malaria
prevention, diagnosis, and treatment; (2) accelerate efforts towards elimination and attainment of
malaria-free status; (3) transform malaria surveillance into a core intervention for tracking of the disease
and taking action in response to the data received. These pillars are supported by implementations for
expansion of research and innovations towards key areas and strengthening the enabling environment,
such as the health systems, capacity building, and empowerment of communities.
Focusing on pillar 1 in our review, prevention includes vector control by means of
insecticide-treated mosquito nets (ITNs) and long-lasting insecticide treated mosquito nets (LLIN), as
well as indoor residual spraying (IRS). Diagnosis has to do with the timely, selective, and sensitive
identification of the disease. Treatment refers to patient management, typically with artemisinin-based
combination therapy (ACT), at the right dose, for efficient cure of the patient.
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Considering the malaria issue from an overall perspective, it is obvious that all three elements
of pillar 1 have interdependencies. Population gets sick because vectors transmit the pathogens.
Patients die because of lack of suitable diagnosis, which, in turn, leads to inappropriate treatment.
This condition creates a complex landscape, involving humans and vectors. It cannot be denied that
these are different aspects of the same issue. Observing the global research initiatives and funds, it
is clear that there is only little done to combine the areas of human and mosquito diagnostics (Dx),
even though both fields can benefit if treated in a converging manner. In fact, this type of thinking
used to be the norm, with large scale field trials of integrated vector control and human interventions
being supported in sub-Saharan Africa [9]. However, with the “failure” in Africa of the World Health
Organization’s Global Malaria Elimination Plan [10], enthusiasm for holistic strategies waned, and
is only now coming back in favor. One example is the study of Kramer et al., where the authors’
primary objective was, “to evaluate the role of disease management (home-based management consisting of
early detection and treatment), vector management (larviciding), and these two interventions in combination,
in malaria control” [11]. Very importantly, in the Global Technical Strategy for Malaria 2016–2030,
the WHO recommends “implementing two sets of interventions in a complementary way: (1) prevention
strategies based on vector control, and, in certain settings and in some population groups, administration of
chemoprevention, and (2) universal diagnosis and prompt effective treatment of malaria in public and private
health facilities and at community level” [8].
Focusing on the aforementioned recommendation by the WHO, this review aims to set some
pathways towards the convergence of the fields of human malaria diagnostics and vector surveillance,
and with easy adaptation and expansion to other vector-borne diseases. These pathways are
as follows: (i) on the molecular diagnostics level, using suitable novel assays (and generally
biochemical components) that are capable to provide multiplexed analysis for human and mosquito
Dx; (ii) the integration of these assays and biochemical components into portable and automated
platforms for deployment in the field; and (iii) the smart interfacing of acquired data through
information and communication technologies (ICT) for strengthening the data management and
surveillance interventions.
We structure the content of this review according to these three pathways, and within each of
them, we discuss commonly the human and vector side, in terms of current state-of-the-art and novel
approaches, in order to demonstrate the close relation between these two fields. In Section 5, we
provide some suggestions for the convergence through behavioral change and discuss the impact of
the proposed holistic approach. The One Health, as a term, refers to “the collaborative efforts of multiple
disciplines working locally, nationally, and globally to attain optimal health for people, animals, plants and
our environment” [12,13]. As this special issue focuses on malaria, the authors directed their analysis
towards this particular disease from the human and the vectors’ perspective as two branches of the One
Health approach. Notably, the technologies that are reviewed and the interconnection that is suggested
(i) between the technologies (vertically) and (ii) between human and vector diagnostics (horizontally)
are applicable for other vector-borne diseases as well, therefore, the reader is urged to consider the
impact and implications on the entire health system, rather than a single health facility/sentinel
site level.
2. Diagnostics
2.1. State-of-the-Art and Challenges in Human Diagnostics
Symptomatic human P. falciparum infection may progress from a mild febrile illness to a severe
and life-threatening disease. Therefore, it is recommended that malaria diagnosis should be available
within a maximum of two hours after patients present themselves in the health facility [14]. Especially,
because many patients might reach the health facility at a very late stage of the disease, rapid diagnosis
and treatment are required. On the other hand, in highly endemic areas, a large proportion of
the population can be infected, but yet have no symptoms, and therefore, a significant number of
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individuals may never be evaluated for infection, but remains as a reservoir of the parasites and indirect
infection source to other people [8]. Assuming a correct diagnosis, the treatment of uncomplicated
P. falciparum malaria consists of a quality-assured artemisinin-based combination therapy. However,
increased resistance to antimalarial drugs (e.g., of P. falciparum to artemisinin in South-East Asia) [15]
are threatening the efforts for malaria elimination, while rendering the treatment inefficient. In addition,
the resistance patterns vary geographically, which makes the situation even more complicated, while
there are currently no available tools for detecting resistances in combination with diagnosis.
Malaria diagnosis may become challenging in case there are co-infections or sudden outbreaks
of epidemics, i.e., interference of other pathogens. This is why malaria should not be examined as
an isolated event in diagnosis. In endemic countries, fever as symptom may be the result of several
non-malaria infections. Some of them may exhibit local symptoms (e.g., gastrointestinal, respiratory,
urinary tract infections), which facilitates differentiation from malaria infection. However these
non-malaria febrile illnesses [16,17] are, in general, the most challenging ones to diagnose because
of the so-called “fever of unknown origin”. Bacterial diseases, such as typhoid fever or pneumonia,
often present the symptoms of malaria, and, in the absence of reliable diagnostic tests, the patient is
given an antimalarial instead of an antibiotic treatment, which can have lethal consequences [18,19].
Moreover, typhoid fever (and salmonellosis in general) often occurs as malaria co-infection [20] and
requires, therefore, to be identified even in the presence of a positive malaria test. In malaria-endemic
regions, many patients are presumptively treated for malaria based on of febrile symptoms alone.
Indicatively, the study of Reyburn et al. reports overdiagnosis of malaria in Tanzania, relating to the
failure to treat alternative causes of severe infection [19]. During epidemics, a common procedure
is to screen all patients for the epidemic-specific pathogen, but not for any other, thereby missing
some co-infections, which may be proven lethal for the patient, as in some cases with dengue [21] and
Ebola [22]. The consequence of misdiagnosis is wrong patient management (e.g., antimalarial when
the patient actually suffers from viral infections; or antibacterial when the patient suffers from malaria).
The impact of wrong treatment is the increase of morbidity and mortality [23], rise of antimicrobial
resistance, and waste of precious pharmaceutical material [24].
The current gold standard in malaria diagnosis is microscopy blood smear tests [25]. In the African
Region, the number of patients examined by microscopy increased from 33 million in 2010 to 48 million
in 2014, while the global total was 203 million microscopy examinations of microscopy slides in
2014 [26]). Although this is one of the most “traditional” approaches, it requires experienced personnel
and thorough sample preparation, while the method is specific only to detect malaria parasites.
Furthermore, microscopy has poor sensitivity in low transmission settings and in asymptomatic
patients, resulting in underestimation of disease prevalence. This is why tools with greater sensitivity
than microscopy are needed in such cases, in order to detect these infection reservoirs [27]. Indicatively,
the study of Okell et al. reports that for P. falciparum, microscopy underestimated prevalence by 50.8%
compared to PCR [28].
Rapid diagnostic tests (RDTs) are lateral flow tests identifying the Plasmodium-specific antigens
histidine-rich protein 2 (HRP2), lactate dehydrogenase (LDH), and aldolase. The matureness level
of some malaria RDTs is quite high, and some of the tests are in the WHO recommendation list [29].
They are fast, cheap, easy-to-use, and mass producible, which justifies their broad use [30], and the
reason why such tests will not be replaced by other techniques, especially for triage tests at remote sites
(RDT manufacturers’ reports showed that RDT sales had more than doubled from 2011 to 2014 [30]).
Yet, a major drawback of RDTs is that each test targets only one disease and, although typically the
first RDT is given for malaria, in case of malaria-negative result, other RDTs have to be sought or
other analyses to be done. Such procedures increase the overall cost as well as time-to-diagnosis and
treatment, especially if the patient needs to travel to a more central health facility. In addition, and
in cases of co-infections, malaria may be correctly diagnosed on one hand, but a co-existing viral
or bacterial infection may be missed, thereby risking the follow-up treatment, if based only on a
malaria-positive RDT. On top of these, and in the broad context of febrile illness diagnosis, we have
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to mention that apart from some of the malaria-specific RDTs, others, e.g., for chikungunya [31], are
of disputed sensitivity or diagnostic value. This was found especially in asymptomatic patients, as
indicated by the study of Cook et al., where the treatment of patients based in RDT diagnosis did not
reduce the malaria incidence [32].
In case of bacterial infections, the gold standard is bacterial culture-based diagnosis. Though highly
sensitive, since even a few cells will be eventually cultured, it is costly, requires much hands-on work and
considerable user expertise, while the time-to-result may be up to 72 h. This method is only capable of
detecting bacteria, thus, any co-infection with viruses or malaria will be missed.
The challenges identified in the above methods, presumed as gold standards, are that: (i) they
all are time-consuming, (ii) they require experienced personnel to be operated, except for the RDTs;
(iii) some of them (e.g., many RDTs) present sub-optimal sensitivity; and (iv) they all lack multiplexity,
as they all detect only one specific disease per examination. Especially for the latter argument, in case
of a malaria-negative result (as malaria is typically the first candidate disease tested in cases of febrile
episodes), the health provider needs to consider follow-up sequential tests to identify the cause of
fever, which adds time, cost, and risk of misdiagnosis and delayed (if at all) treatment.
The solution to this major issue lies in the differential diagnosis of fever by means of (i) sensitive
and specific identification of the pathogen (species) itself through detecting its genetic profile, and
(ii) multiplexity, i.e., simultaneous detection of several potential fever-causing agents. These requirements
are met by means of molecular diagnostic tests (Nucleic Acid Amplification Tests–NAAT [33–35]).
Apart from their implementation in diagnosis, NAAT, in general, can be used in malaria
programs and interventions for epidemiological research as well as surveys to map infections in
low-transmission areas. Such methods could also be used for identifying foci for special interventions
in elimination settings [36].
PCR started being employed in malaria diagnosis in the 2000s, and has proven to be very specific
and sensitive, especially in cases of low parasitemia and co-infections. Even though microscopy and
RDTs are still considered as the gold standards, PCR is often used as confirmatory method when
results from traditional gold standard methods are unclear [37,38]. Currently in African laboratories
there are two main PCR methods followed, namely the conventional PCR (gene amplified and detected
using gel-electrophoresis, result is qualitative) and the real-time PCR (real-time monitoring of the
reaction). The disadvantage of the former is that it takes place in an open system and requires tedious
pre- and post-PCR sample handling and processing. This is overcome through real-time PCR using
probes (e.g., FRET [39], TaqMan probe [40]), or intercalating dyes (e.g., SYBR green [41] real-time
PCR), eliminating the need for post-PCR handling. Real-time PCR is currently the most widely used
technique, not only for malaria detection and species identification and differentiation, but also for
antimalarial drug resistance screening [42]. As it is carried out in closed environment (tubes) it is
less prone to contamination and more suitable for automation. In addition, real-time PCR offers the
possibility of high throughput and standardization [43], as well as quantification of the parasite load.
This is of particular importance in the case of low-parasitemia patients, as well as when elimination
(and not simply screening) is the scope of the test. An overview of malaria PCR can be found in the
UNITAID 2016 Malaria Diagnostics Technology and Market Landscape Report [33].
Isothermal amplification technologies are comparatively novel methods that do not require
thermocycling, like PCR, thus becoming more attractive in terms of reduced protocol complexity [44].
Due to their isothermal nature, they require lower power consumption than PCR, which renders
them good candidates for resource- and infrastructure-limited settings. On the other hand, a main
disadvantage of isothermal technologies is the fact that they cannot be quantitative, nor achieve a high
degree of color-based multiplexing (e.g., 4-plex per reaction) like the real-time TaqMan probe PCR.
Out of the available isothermal technologies currently being developed, the loop-mediated isothermal
amplification (LAMP) [45,46] is the most frequently implemented in malaria diagnosis, mainly due
to the fact that it uses 6 primer sets per target, thereby offering high specificity. It is compatible
with turbimetry-based naked-eye detection, which requires a simplified detection instrumentation.
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The reaction takes place at a constant temperature of 64 ◦C. LAMP for malaria diagnosis has been
used by various groups recently [47], in endemic areas such as India [48], Latin America [49], but even
for detecting traveler-imported malaria in non-endemic areas, like Switzerland [50]. Recent studies
report the development of real-time LAMP assays using SYBR green for real-time detection, rather
than using visual color change, interestingly, amplifying the targets (P. falciparum) from directly boiled
blood samples [51]. To this direction of real-time LAMP, one step has been further accomplished to
detect other non-malaria fever-related tropical infections, such as dengue [52] and chikungunya [53],
using reverse transcriptase real-time (RT)-LAMP.
2.2. State-of-the-Art and Challenges in Vector Diagnostics
Mosquito surveillance builds the foundation of every effective, efficient, and environmentally
sustainable vector control program. Information on the species composition of the local vector
population, alongside the knowledge on pathogen infection and insecticide resistance prevalence, is
crucial for decision makers of vector control interventions [54].
Accurate species identification is essential to discriminate vector from non-vector species.
Moreover, knowing the species composition can give an indication of the basic biology and behavior
of a vector population. For example, breeding site preferences and host-seeking, biting, and
resting behavior are often species-specific characteristics that offer potential targets for control
interventions. Species identification is primarily carried out by microscopic examination of specimen
using morphological keys. However, several African malaria vectors within the An. gambiae complex
or An. funestus group present overlapping morphological characteristics and geographical distribution
with other vectors and non-vectors. Anopheles spp. often represent a complex of several mosquito
species that cannot be distinguished using morphological criteria. However, some of these species
can occur sympatrically, and at the same time, they differ in their ability to transmit malaria and in
their behavior (anthropophilic or zoophilic). For the task of species identification, the focus turned
to molecular methods, with allele specific PCR (AS-PCR), restriction fragment length polymorphism
PCR (RFLP-PCR) and multiplex TaqMan qPCR assays being the most used methods [54,55].
Regarding malaria, the detection at the infective stage of the four human-specific species
P. falciparum, P. vivax, P. ovale, and P. malariae within Anopheles mosquito hosts worldwide
(e.g., An. gambiae, An. funestus, An. sacharovi, An. minimus, An. stephsensi, An. sinensis, etc.) is of prime
importance for vector control programs [54–56]. The detection of Plasmodium-infected mosquitoes has
been traditionally performed by microscopically assessing the presence of sporozoites in dissected
salivary glands [26]. This procedure may be infective stage-specific, but nowadays seems obsolete;
as it is time- and resource-consuming, it requires experienced personnel and cannot differentially
discriminate Plasmodium species. Enzyme-linked immunosorbent assays (ELISAs) targeting the
infective stage specific circumsporozoite protein (CSP) of P. falciparum [57] or P. vivax [58] have been
proposed as a rapid high-throughput method to screen potentially malaria-infected mosquitoes.
However, these ELISAs have several limitations, as both their sensitivity and specificity are low,
and most importantly, they have been shown to overestimate mosquito infection rates [59–61].
An alternative way to address the abovementioned limitations is the introduction of PCR-based
molecular assays for the detection of Plasmodium in mosquitoes. Nested PCR approaches have
been proposed [62], but they require two separate PCR reactions (low throughput, high cost),
post-PCR interventions (agarose gel electrophoresis), and are prone to contamination, especially
in a low-resources laboratory environment (no isolated/controlled PCR rooms). Single-round PCR
approaches [63] have also been developed, but are less sensitive. Real-time PCR-based assays have
been proposed as a more sensitive method of Plasmodium detection, with the TaqMan assay of Bass et al.
being the most operationally relevant. This assay is rapid, requires no post-PCR processing, and can
discriminate P. falciparum from P. vivax, P. ovale, and P. malariae [64]. However, because this method
detects all mosquito stages of Plasmodium, the abdomen must be removed prior to extraction, in
order to increase the chance of only detecting the infective sporozoites residing in the salivary glands
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e.g., in the head–thorax region. A novel TaqMan assay was recently developed, capable of detecting
the infective stage of the Plasmodium parasite by measuring the mRNA levels that are specifically
expressed at the infective parasite stage, the sporozoites. This method does not require head/thorax
dissections, and can be used in mosquito pools, in single or multiplex formats, i.e., also targeting
additional markers expressed in different tissues, such as detoxification enzymes associated with
insecticide resistance [65].
Determination of insecticide resistance [66] using bioassays is a main component of Insecticide
Resistance Management (IRM) programs. In general, bioassays can adequately determine if moderate
to high levels of resistance are present, without investigating the underlying molecular mechanism.
Insecticide resistance is usually assessed by two types of bioassays. Mosquitoes are either exposed
to a single dose of an insecticide for a predefined time (prevalence bioassays) or mosquito mortality
is recorded across a series of insecticide concentrations or exposure periods (quantifying bioassays).
Prevalence bioassays are logistically easier to perform, but may be not as operationally informative
as quantitative bioassays, which can be, in turn, impractical for widespread monitoring. In either
case, bioassays involve methodological steps that are difficult to reproduce, require large numbers
of live insects, can be affected from environmental factors, and cannot accurately detect low levels
of resistance [67,68].
The underlying genetic mechanisms for insecticide resistance can be divided into two groups:
target-site resistance and metabolic resistance. The sensitivity of insecticide target site is affected by
non-silent point mutations, whereas the cause for metabolic resistance is overexpression of enzymes
that detoxify or sequester insecticides. Molecular diagnostics for the determination of insecticide
resistance can address most of these complexities, because they are more rapid, sensitive, and
reproducible. They can detect resistance at its very early phase of development and monitor its
increase. In this way, they can provide more reliable and evidence-based indications to whether
changes are needed in insecticidal strategy, i.e., change of insecticidal regime due to detection of
molecular alterations associated with the resistance to this particular insecticide. Again, multiplexing
is essential for this task in order to determine the molecular aberrations that are causally related to
insecticide resistance. Both target-site mutations and metabolic resistance can be robustly detected
with the use of TaqMan-based molecular diagnostics [62,63,69].
A well-characterized mechanism of resistance to DDT and pyrethroids is caused by point
mutations commonly referred to as knockdown resistance (kdr) mutations (L1014F, L1014S, N1575Y)
of the insecticide target site, the para-type sodium channel. Detection of kdr mutations can be achieved
by several assays that determine the presence of the mutant kdr alleles, such as the TaqMan assays,
the AS-PCR, the heated oligonucleotide ligation assay (HOLA), the sequence specific oligonucleotide
probe-enzyme-linked immunosorbent assay (SSOP-ELISA) and the PCR-dot blot [70–73].
Similarly, resistance to organophosphate and carbamate insecticides that can result from
insensitivity of the target site enzyme, acetylcholinesterase (ace), can be detected by both TaqMan and
conventional PCR-RFLP assays [74,75].
Determination of detoxification gene overexpression at the mRNA level can pinpoint aberrant
expression of specific members of detoxification gene families in association with insecticide resistance.
The main approaches that have been used to determine gene expression levels of genes associated
with insecticide resistance are microarrays and singleplex qPCR using the SYBR Green chemistry,
while ELISA immunodiagnostic protocols have been employed for the detection of detoxification
enzymes in agricultural pests [76]. Microarrays have been used to screen insecticide resistant laboratory
and field populations for detoxification gene deregulation; however, these do not represent a viable
routine diagnostic approach, in terms of cost and complexity of analysis. Detoxification loci that have
already been identified to be associated with insecticide resistance in several Anopheles species (e.g., the
cytochrome P450 monooxygenases CYP6P3, CYP6M2, CYP6P4, and CYP6Z, and the glutathione-S
transferase GSTE2 in An. gambiae) may be targeted by a singleplex SYBR-Green based qPCR [77–79].
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Multiplex TaqMan assays for the simultaneous determination of the mRNA expression levels of this
“short list” of insecticide-resistant related genes are currently under development [80].
2.3. Progress beyond the State-of-the-Art
Concluding from the aforementioned sections, the current needs and trends in both human and
mosquito diagnostics, as one of the three proposed pathways to bridge these two fields, are (i) genetic
profiling of pathogens (in case of human Dx) and species/resistance patterns (in case of mosquito Dx)
by means of NAAT, and (ii) multiplexing of the NAAT. In order to establish a “diagnostic bridge”, the
molecular assays seem ideal for several reasons (Figure 1):
1. They offer the capability of multiplexing, thus increasing throughput without the need of costly
and complex analysis methodologies, such as microarrays.
2. They are diagnostically robust, they offer high sensitivity and specificity, they have been
introduced in routine laboratory use for years, and are applicable to most laboratory settings.
3. The exact same assays that are used in human diagnostics for pathogen detection can also be
used in vector diagnostics (exact same species/serotypes/lineages of pathogens can be detected),
thus making epidemiological information more universal.
4. Both DNA and RNA determinations can be performed with exactly the same methodology from
sample preparation to measurement.
5. Especially TaqMan PCR allows (semi)quantitative information about the degree of infection
in humans, enabling a correlation between the Ct value and the pathogen concentration
(parasite/bacterium/virus).
6. They can be integrated in an automated platform.
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3. Packaging into Portable and Automated Platforms
3.1. Automation and Integration
The NAAT described in Section 2 are established on benchtop equipment and performed by
experienced personnel, who use manual protocols mainly at central laboratories. In developed
countries, this model is compatible with the degree of training of personnel, matureness of health
systems, laboratory infrastructure, and affordability by the patients. However, in developing countries,
the conditions are mostly prohibiting for use of such NAAT in central laboratories, because of the
following reasons: (i) the personnel has often undergone limited training, therefore, the diagnostic
procedure must be as easy-to-handle and as automated as possible; (ii) much of the population lives
far from the capitals or big urban centers, therefore, the diagnosis must be done at the point-of-care
(POC) instead of central laboratories; (iii) infrastructure may often be poor or not sustainably available
(e.g., intermittent electricity), thus, the diagnostic process must be power-independent, or at least
operable with alternative means of power, like solar energy; (iv) the environmental conditions (high
temperature and humidity especially around the tropics) and lack of reagent storage facilities require
independence from cold chain transport; (v) the per capita income of the population does not allow
expensive diagnostic tests, thus, the affordability and production capacity must be taken care of.
The above conditions have shaped the so-called ASSURED criteria by the WHO [81], which
summarize some basic features that should be fulfilled by the “ideal” diagnostic test for the
developing world, namely affordable by the target groups; sensitive and specific; user-friendly
for limited trained personnel; rapid and robust; equipment-free; and delivered to those in need.
For specific applications, there are specific Target Product Profiles (TPPs) composed by experts
to describe the minimum requirements of diagnostic tools [82,83]. These requirements have led
to the packaging of the aforementioned NAAT in integrated and automated platforms under the
“triangle”: assays–cartridge–instrument (Figure 2). The “assays” perspective was described in Section 2.
The “cartridge” and “instrument” are described in this section.
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Figure 2. The “triangle” assays–cartridge–instrument lies in the heart of automated point-of-need
platforms (here point-of-“need” is used as a more general term to include the mosquito diagnostics
instead of point-of-“care” that is typically used for human diagnostics). This structure is common for
any platform-oriented approach, and the concept of unified human and mosquito diagnostics can build
upon this configuration. Source: K. Mitsakakis, Hahn-Schickard.
Int. J. Environ. Res. Public Health 2018, 15, 259 10 of 26
In terms of cartridges, most technologies are based on plastic or silicon disposable microfluidic
chips [84]. Their fabrication technologies are usually rapid prototyping (for plastic), or standard
MEMS (MicroElectroMechanical Systems) technologies (for silicon), which are then transferred to
batch scale-up molding production. Such microfluidic cartridges are called micro total analysis
systems (µTAS), and they integrate and miniaturize operations that would otherwise need an entire
laboratory to be performed. In order to achieve this, assay developers and microsystems engineers
collaborate in order to define the assay protocol, and break it down into sequential steps, which are
then translated into so-called microfluidic unit operations [85]. The latter are interfaced towards
the final sample-to-answer cartridge, which integrates the complete workflow required for NAAT,
including sample preparation. The heterogeneous integration of all (bio)chemical components into
the cartridge is a challenging, but necessary procedure, in order to achieve a fully integrated and
automated analysis and avoid any user hands-on steps and interference. In particular, for molecular
diagnostics integration, primers/probes are typically dry-stored [86], while unspecific amplification
reagents, such as polymerase and reverse transcriptase enzymes, are typically stored in a lyophilized
format [87,88]. In addition, for sample preparation using boom chemistry [89], nucleic acid extraction
reagents need to be pre-stored as well. These are buffers for lysis of pathogens and subsequent
purification of the DNA/RNA, as well as (magnetic) silica beads in case of bead-based extraction
kits [90]. The integration of all biochemical processes imposes also the use of suitable controls, in
order to ensure the non-failure of all the integrated procedures. These controls are typically in the
form of extraction control, where a model organism undergoes the same extraction procedure as the
unknown pathogens in the sample, and amplification control, where primers specific to this organism
are amplified together (in the same amplification location/chamber) with the target [91,92].
The handling of cartridges is done by a dedicated instrument, which facilitates the temperature
protocols for thermocycling, or isothermal conditions. The instrument also provides the environment
for handling the microfluidics of the cartridge (capillary-, pressure-, or centrifugally-driven). Finally, it
also integrates the modules for the multiplex real-time signal detection of nucleic acid amplification.
Instruments utilizing infrared heating or contact heating can achieve rapid heating/cooling rates,
thereby speeding up the real-time PCR. From the haptics perspective, the instrument engineering
provides compact solutions, as some of the marketed near-patient or point-of-care devices are already
portable or semi-portable (Table 1). Overall, the role of automated sample-to-answer platforms is to
1. Provide the suitable interface for safe and contamination-free sample inlet. The sample inlet
should be of universal nature in order to facilitate analysis from different matrices, such as whole
blood, serum, sputum (in case of tuberculosis), or swab transport medium (in case of respiratory
infections), but also mosquito homogenate samples.
2. Automate sample preparation and interface it on the same cartridge with the NAAT mentioned
in Section 2.
3. Integrate and in situ store (bio)chemical reagents that are required for sample-to-answer analysis.
4. Use a processing instrument, which incorporates the detection technology and reporting interface.
5. Be adaptable in exchanging the desired targets according to endemic and epidemic needs, and
geographical requirements.
3.2. State-of-the-Art in Automated Detection Technologies
Screening the technological landscape, one can find several technologies for rapid analysis of
nucleic acids. However, going deeper into the screening, the number of candidate technologies that
can sufficiently respond to the requirements set out in Section 3.1 decreases significantly. Table 1
summarizes some of the main technologies and their performance characteristics. Inclusion criteria
were that these specific technologies: (i) make use of NAAT; (ii) analyze at least in 2-plex level; (iii) are
integrated sample-to-answer platforms, following the concept of Figure 2; (iv) are at late development,
near-market, or at-market stage. From the listed technologies, only few are focusing on malaria and/or
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generally tropical infections for human diagnostics, and only one focuses on both human and vector
diagnostics; that is why we choose to elaborate only on these in the current review. Mitsakakis et al.
are preparing a more comprehensive overview of all these technologies [93]. For malaria diagnostic
technologies at lower readiness levels, an overview is given in the 2016 UNITAID Malaria Diagnostics
Technology and Market Landscape Report [33].
3.2.1. VerePLEXTM Biosystem
The platform has been developed through a joint effort of the STMicroelectronics, Italy, the
Agency for Science, Technology and Research (A*STAR), Singapore, and Veredus Laboratories,
Singapore. Several cartridges have been developed according to applications in demand (e.g., influenza,
veterinary, biothreat agents). Among them, the VereTropTM chip includes a panel of 13 tropical
diseases [94]. It is one of the very few platforms offering such degree of multiplexity for this kind of
application. Technology-wise, the system needs two processing devices, one for the multiplex PCR and
hybridization, and one for the CCD (Charged-Coupled Device) imaging-based microarray detection.
This rises the total analysis time to approximately 3.5 h. The technology is currently at market stage.
3.2.2. Q-POCTM
Q-POC™ from QuantumDx [95] is a handheld, battery-powered molecular diagnostic device,
performing sample-to-answer DNA detection, offering, additionally, the option for drug susceptibility
test. Its time-to-result is approximately 20 min, and its throughput analysis is based on its nanowire
array biosensor chip. The nanowires are functionalized with nucleic acid probes to capture targeted
sequences of genetic material, thereby enabling SNP and pathogen detection. The technology is capable
of providing qualitative results for five malaria-causing species per disposable cartridge. QuantumDx
aims to use the system at the primary care and for triage testing at the community level, where the
majority of malaria patients are located. The technology is currently at near-market stage.
3.2.3. LabDisk
This centrifugal microfluidic platform has been/is being used in both fields of human and
vector diagnostics. The LabDisk platform is a disk-shaped microfluidic cartridge that is handled
by a LabDisk processing device, and offers a high degree of multiplexing based on geometric
compartmentalization of the assays in distinct reaction chambers, in addition to color multiplexing per
reaction chamber [96,97]. A recent version of the system makes use of 12 chambers (i.e., detection of
up to 12 different human pathogens) which, in addition to 3-plex color multiplexing can give, in future,
rise to a 36-plex detection configuration, especially for species identification, pathogen detection, and
insecticide resistances. It has been recently used in some validation studies in Senegal and Sudan
using a multiplex tropical infection panel (including malaria P. falciparum, P. vivax, P. malariae [98]),
and is under development for the first proof of principle using mosquito samples [80]. The total
time-to-answer is 2 h using LAMP. The technology is currently at late development stage.
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Table 1. Performance characteristics of automated platforms that are already used in malaria diagnosis or are used for other infectious diseases and have the potential
to be expanded to malaria.





Omni: portable Up to 6 60 min No; Omni: Yes No
FilmArray® Nested multiplex RT-qPCR; array-based detection Benchtop 27 60 min No No
AlereTM i NEAR d (isothermal) Portable 2 15 min Yes No
Enigma® ML RT-qPCR Benchtop (modular) 3 95 min Yes No
cobas® Liat RT-qPCR Portable 3 20 min Yes No
EasyNATTM CPA e (isothermal); visual readout in lateral flow strip Handheld 1 90 min Yes No
Verigene® RP Flex System RT-qPCR, gold nanoparticle detection Benchtop (modular) 16 2 h Yes No
GenePOCTM RT-qPCR Benchtop 12 60 min Yes No
Liaison® MDX RT-qPCR Benchtop 4 60 min No No
VerePLEXTM Biosystem PCR and microarray hybridization Benchtop 13 ~3.5 h No In humans only
Q-POCTM qPCR Handheld 5 15 min Yes In humans only
LabDisk
(FeverDisk; demonstrator) RT-LAMP Portable 12 2 h No In humans
LabDisk (VectorDisk;
under development) RT-qPCR Portable 36 Target: 2 h No In vectors
a “Benchtop” means that it is not transportable. “Modular” means that more than one testing units can be connected to the same, single controller unit; b number of targets detected per
cartridge; c “Yes” means it does not need a laptop and the handling is integrated on the device; d nicking enzyme amplification reaction; e cross priming amplification.
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4. Inclusion of Information and Communication Technologies
4.1. Clinical Algorithms for Patient Management
In a world of increasing connectivity, the information and communication technologies (ICT) play
a significant role in the health sector. Considering that the results deriving from automated platforms
like those described in Section 3 are simply numbers, there is a gap between these results and the
clinical outcome. The ICT for health (otherwise termed “eHealth”, or “digital health”) can bridge this
gap by means of suitable reporting tools, which take the diagnostic output data and combine/process
them with suitable clinical algorithms in order to provide a decision support. Importantly, the aim
of ICT is not to replace clinicians, but to assist them in decision making for patient management and
rational prescriptions, especially in areas like malaria diagnosis in developing countries, where (i) the
training of the clinicians may be limited; (ii) the possible causes of fever may not be malaria, or only
malaria, but some other (co)-infections; (iii) epidemics often occur, whose pathogens exhibit the same
symptoms like with malaria, thereby making clinical decisions inherently complicated. Such a decision
support ICT platform is absolutely important, especially when data from multiplexed analyses need
to be co-assessed, or when protein and nucleic acid analysis results need to be combined, along with
the clinical symptoms and the history of the patient. Such platforms are operable on mobile systems,
e.g., phones or, better, tablets, especially as the ICT penetration in developing countries is growing
rapidly [99,100].
A detailed description of eHealth tools that have been/are being used for the management of
fever is available at Mitsakakis et al. [93]. Some examples of such algorithms are as follows (Figure 3):
The e-IMCI (“Integrated Management of Childhood Illness”), the computerized version of the IMCI
developed by the WHO and UNICEF [101,102]. That platform did not take into account non-malaria
causes of fever, such as the typhoid fever. Furthermore, viral diseases were not included in the e-IMCI,
even though among children, the viral infections are one of the most common type of infections. Thus,
the next generation of algorithm, the e-ALMANACH (ALgorithm for the MANAgement of CHildhood
illness), was developed by Valérie D’Acremont and Blaise Genton at the Swiss Tropical and Public
Health Institute [103]. The main upgrade was the inclusion of a broader set of possible diseases in the
algorithm branch, based on the causes of global childhood mortality and morbidity from the Child
Health Epidemiology Reference Group (CHERG). The impact of e-ALMANACH, in terms of health
outcome and rational use of antimicrobials in the routine practice, was demonstrated through the
drastic reduction of antibiotic prescriptions compared to the routine care [104]. An upgraded version of
e-ALMANACH, called the e-POCT [105] combines (i) key clinical elements (demographics, symptoms
and signs); (ii) input from sensors connected directly to a tablet and detecting parameters of severe
illness (e.g., hypoxemia, tachycardia, severe anemia, and hypoglycemia); (iii) clinical predictor factors
(e.g., fast breathing); (iv) results from a series of POC tests for host biomarkers, in particular, C-reactive
protein (CRP) and procalcitonin (PCT). All these are used as data input into a tablet hosting the e-POCT
algorithm. Its output provides (i) diagnostic classification(s) of disease(s) with its (their) probability;
(ii) recommended immediate and/or hospital/home treatments (with dosage based on age/weight);
and (iii) advice on admission versus discharge home. The algorithm is built into an android tablet
using an Open Data Kit (ODK)-based software.
4.2. Surveillance and Data Management
4.2.1. Surveillance in Human Diagnostics
Main features of epidemics are their sudden outbreak and rapid spread, therefore, close
surveillance is mandatory, i.e., continuous, systematic collection, analysis, and interpretation of health
data, confirmation and response to the epidemic, as well as planning, implementation, and evaluation
of public health practices at any level of the health system. One way of epidemic surveillance is the
early identification at the sentinel sites, which are health facilities or reporting sites, representative of
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an area, designated for early warning of pandemic/epidemic events. There, several epidemic-relevant
pathogens (even those that cannot receive treatment, like dengue or Ebola viruses) are to be screened
on a regular basis, and results be registered on a central server system. Over the long term, this would
give valuable information to the authorities regarding potential outbreaks (e.g., if dengue levels in a
community increase dramatically and unexpectedly within a short period of time). However, problems
in the implementation were identified due to the low quality and integrity of data inserted in the
platforms, being related to the manual handling of data deriving for example from RDTs. Towards this
direction, and in order to strengthen the availability and use of surveillance and diagnostic data
for identifying and reporting major diseases globally, the WHO Africa Regional Office set up the
Integrated Disease Surveillance and Response (IDSR) [106], which started to be implemented in Africa
in 2005 through an electronic surveillance tool called DHIS2 [107]. The DHIS2 (Figure 3) allows
data management through visual elements such as charts, tables, and even maps, corresponding to
geographical features. It enables the user to enter data from a variety of devices, thereby offering the
opportunity to POC tests to be deployed at sentinel sites, and remotely send their acquired data in
real-time to central data repositories. The latter are connected with the alarm units of health authorities,
which will then be able to trace, early enough, the outbreak of an epidemic, and trigger actions in
order to prevent it from expanding into a pandemic. The DHIS2, as well as several custom-built
geographic information system (GIS)-based platforms, underpin the malaria surveillance systems in
several countries (for review, see Ohrt et al. [108]). However, one inherent flaw in these systems is their
focus only on disease in human populations. There is limited flexibility to incorporate entomological
or intervention monitoring data, which is needed to support operational decision making.
4.2.2. Data Management Systems in Entomology and Modern Communication Tools
Surveillance systems for insect vectors lag behind the digital technologies available for human
disease surveillance. There are several examples of sophisticated vector surveillance tools that provide
real-time decision support for vector control operations, but they typically exist in more developed
countries. One example of such a system is the Gateway, the digital technology which underpins
the California Vectorborne Disease Surveillance System in the United States (www.calsurv.org).
This software has been in use by local vector control programs since 2006, and has been the foundation
of operational decision-making. Decision support is facilitated by the rapid transformation of
raw data into actionable information through the production of reports, graphs, and maps [109].
Unfortunately, in many malaria-endemic areas, the capacity to build and maintain such a system for
the purposes of anopheline surveillance activities is lacking. As a result, a major problem has been
the poor organization and integration of the large volumes of entomological data that are obtained in
resource-limited malaria endemic countries every day, as well as the interpretation, utilization, and
communication of these data. Often, different entomologists in a country store data in combinations of
hard copies, or Microsoft Excel® and Microsoft Access® databases, resulting in a fragmented series of
datasets. These data storage methods are unable to supply programs with accessible, consistent, or
accurate data. Over time, a number of programs have gone on to develop fragmented systems to deal
with different data sets as the program itself grows. This has led to an inherent problem of fragmented
data, for which there is no easy way to reconcile and analyze in a systematic manner.
4.2.3. An Integrated Data Management and Decision-Support System
The Disease Data Management System (DDMS) [110] is a data management software program
(smart database) with the capability to collect data from routine entomological, epidemiological, and
intervention monitoring activities, and store and make available stratified information on malaria risk
and vector populations based on “user queries” in a standardized way [111]. It was designed to be
as flexible as possible, and implementable with little existing technological capacity or infrastructure.
It has been used by disease control programs to efficiently manage and integrate some entomological
data and convert information into user-friendly formats for operational use [112]. The data can
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be presented to the users based in their “choice” (user queries) into customized reports, maps,
graphs, images, and tables, providing, thus, a versatile and comprehensive picture of entomological
and operational data to support operational decisions of disease control program members and
stakeholders [80]. The DDMS database (Figure 3) can manage data at both the aggregated and
individual level, including from other databases related to Public Health (such as Health Management
Information Systems and Indoor Residual Spray Databases), thus avoiding duplication of effort and
the implementation of parallel systems.
Some of the features of the DDMS are (i) software flexibility, which allows full customization to
local conditions; (ii) easy import of archived data from legacy systems; (iii) conversion of information
into a wide range of reports, maps, and graphs; (iv) customized queries and reports; (v) full export
function, which enables data to be used in other applications; (vi) strong geographic information system
(GIS) component, which allows users to examine their data via an interactive map [80]. The impact
of having a DDMS connected with systems of generating diagnostic and entomological data, in
combination, is the continuous surveillance, monitoring, and evaluation using real-time data, the
decision support for vector control strategies by malaria control programs, and the identification of
disease prevalence, in order to plan and monitor specific interventions.
4.3. Serious Games
Effective vector control is dependent on insecticide resistance management (IRM), but in order to
manage resistance, the core principles, appropriate methodologies, and benefits need to be well
understood. Traditional communication and learning tools, such as guideline documents and
large-scale workshops, have not accomplished the outcomes in IRM, which would be expected from
such extensive education programs. The biological complexity of the molecular entomological data
and insecticide resistance also present an obstacle to uptake within operational programs. The global
community understands that the development of innovative methods of communication and learning
to bridge this translational gap are urgently required. However, there is no current global consensus
on how to individually or collectively address this.
The use of “Serious Games” (Figure 3) for improving communication and interpretation of data in
public health initiatives is a growing trend [113]. According to Abt, 1970, “Serious Games have an explicit
and carefully thought-out educational purpose and are not intended to be played primarily for amusement.
This does not mean that serious games are not, or should not be, entertaining” [114]. Until 2014, Serious
Games had never been introduced as innovative communication and educational tools to improve
vector control programs. Nevertheless, the development of a Serious Game to assist African partner
countries to better understand the use of data and to promote informed decisions for insecticide
resistance management has been recently initiated by the Liverpool School of Tropical Medicine
(LSTM), in cooperation with the Innovative Vector Control Consortium (IVCC). This Serious Game
employs interactive ways of communicating guidelines and exemplifying good practices of successful
insecticide resistance management use in the health sector, and has gone through initial development
and successful pilot application testing in two resource-limited locations. The Game effectively
communicates vector disease data and guidelines to national malaria control programs. It can be
interfaced with disease data management systems and diagnostic tools and be used to educate
end-user communities about the usefulness and value of these data, as well as teach the end-users
how to best understand these data in terms of vector control and insecticide resistance management
practices. Within the context of vector control, this Serious Game can assist traditional methods of
decision making by: providing an interactive way of communicating and learning from guidelines
and good practices for operational program levels; bridging translational gaps; and turning high
level policy into effective operational practice. It also allows end-users to explore complex problems
in a safe environment, allowing them to make mistakes and learn from them without real-world
consequences [80].
Int. J. Environ. Res. Public Health 2018, 15, 259 16 of 26
Serious Games have also been implemented in the field of malaria detection in human diagnosis,
for example, for parasite quantification, through an online game for analyzing images of infected thick
blood smears. There, it was shown that, within 1 month, anonymous players from 95 countries played
more than 12,000 games and generated a database of more than 270,000 clicks on the test images.
Results revealed that combining 22 games from non-expert players achieved a parasite counting
accuracy higher than 99% [115]. Along the same line, Mavandadi et al. developed a crowd-sourcing
and distributed gaming platform that allows individuals from anywhere in the world to assist in
identifying malaria infected red blood cells (RBCs) imaged under light microscopes [116].
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5. Behavioral Change and Impact of a Holistic Approach
Even though there is evidence that the areas of human and mosquito diagnostics should not be
treated separately, but there are several sub-areas that could be treated convergingly, such changes
in mentality and strategy do not always take place easily and rapidly. For this reason, a set of
behavioral changes should be accomplished mainly by the involved stakeholders. Some propositions
are described below.
From the malaria control programs and NGOs perspective: Very positively, the WHO in its
recently published Global Technical Strategy for Malaria 2016–2030 Agenda declares in pillar 1 that
prevention strategies based on vector control and universal diagnosis are two sets of interventions
that should be implemented in a complementary way [8]. More initiatives need to be taken, however,
at operational levels closer to the health technologies. For example, NGOs from the human and
vector diagnostics could cooperate and set up Target Product Profiles (TPPs), i.e., a set of performance
specifications addressed to technology developers/manufacturers, for tools, assays, and ICT platforms
that would be developed or upgraded along the direction of human/vector Dx convergence, so as
to “synchronize” studies, analyses, data, and outcomes in these two sectors. In parallel, and to avoid
reluctance from commercial partners/manufacturers, initiatives could be taken for updated business
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models that would take into account that commercial opportunities are enhanced when one considers
both sectors as target groups for their products. This would give additional incentives to innovators to
target both applications with the same intensity, and not underestimate one of the two.
From the intellectual property (IP) perspective, which is a key factor in innovation: The complicated
IP situation with respect to integrated µTAS represents a major inhibiting factor for their introduction into
low- and middle-income countries. When looking into the background IP of a mature sample-to-answer
NAAT, a multitude of patents protect the integrated components. It is clear that stakeholders generating
IP should be reimbursed for their efforts and ideas. However, it is, in general, difficult to find satisfying
license agreements for all involved parties. An idea to solve this dilemma was proposed in the past by
the Médécins Sans Frontières (MSF) with regard to so-called “fixed-dose combinations” (FDCs) [117]
for effective treatment of HIV or tuberculosis. Patent holders may put their patents into such a pool
so that such pills combine multiple drugs initially developed by different institutions or companies.
Extrapolating from this example of pharmaceutical industries, lessons can be learned, and diagnostic
developers/innovators, as well as assay developers from the human and the vector fields, may pool
their IP in a similar manner and use the combined package of patents to develop, in this case, the
integrated systems. Then, patent holders are reimbursed via license fees. There is a huge need to
offer, in future, patent pools that collect the underlying patents and help to make them accessible for
such systems.
From the technology developer/innovator perspective: They should design their technologies in
such a way as to be compatible with the diagnostic needs of both human and mosquito targets.
For example, when designing malaria assays, amplification reagents should be as universal as
possible. Similarly, the extraction kits for purifying the DNA/RNA should be made compatible
with whole blood/serum (typical sample matrix for human malaria diagnosis) as well as mosquitoes
freshly homogenized or after storage in RNAlater® (Ambion™ Inc., Austin, TX, USA)—an aqueous,
non-toxic tissue storage reagent that rapidly permeates tissue to stabilize and protect RNA in unfrozen
specimens—which is the typical sample matrix for mosquito analyses. The cartridges that process
the human and the mosquito samples should be made as universal as possible, in terms of design
and unit operations. This way, at the transfer from prototyping to large scale manufacturing, the
compatibility of the cartridges with both diagnostic sectors would significantly save manufacturing
costs. At the same time, the biochemistry that offers the species-specificity, i.e., the primers, should be
easily exchangeable upon demand, but always keeping the rest of cartridge components the same.
From the ICT (data management and communication) perspective: Key stakeholders could
organize joint workshops so as to bring experts from the two fields under the same roof, making use
of ICT platforms and facilities which are increasingly implemented in the majority of the developing
countries. Tutorials would add impact to this, especially if they are embedded in platforms that
end-users have already been familiar with, such as the Serious Games (Section 4.3). For example, and
for a Serious Game addressing entomologists, a mini video could be embedded that would emphasize
the importance of sharing data with the human diagnostics community, exchanging information
about interventions and results. Thus, it would gradually become a conscience to the malaria
program managers that the convergence is of mutual benefit. An issue of utmost importance in ICT
implementation is the interoperability between the data management platforms of human diagnostics
and vector epidemiology. The impact would be great, as the interoperability between data and
diagnostic platforms would lead to a broad database, more efficient surveillance, and early epidemics
containment. In addition, interventions would be able to be monitored by individual platforms, for
example, an intervention of new insecticide implementation (typical entomological intervention), what
influence it has on the reduction (or not) of incidents on humans in the particular region (and perhaps
even in combination with specific antimalarial treatment on the patients). Thus, although it is probable
that diagnostic tools described in Section 3 may not be used by the same personnel (epidemiologists
versus clinicians), the impact is not restricted on a local/health facility/sentinel level, but should be
viewed at a higher level: (i) from the entire health system perspective, where data from various sources
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will be processed altogether, and interventions on mosquitoes and humans will be co-assessed for
more informed decisions, management, and control, and (ii) from the manufacturing/procurement
perspective, where manufacturers of diagnostics (assays, kits, cartridges, instruments) will find more
attractive business models and financial incentives when their market will be unified rather than
fragmented. This will, in turn, lead to more manufacturers being active in the field, thus increasing the
competition and the quality of the diagnostic and ICT platforms.
From the One Health perspective: an important additional component of a holistic approach
is the animal health. Addressing the interplay between malaria, animals, and humans, we make a
general distinction between the wildlife and the domestic animals. A striking example of the influence
of wildlife in zoonotic malaria is the prevalence in South-East Asia of the P. knowlesi species [118].
Its natural host is a macaque monkey, but when it infects humans, it may cause fatal complications.
It was only recently, in 2004, that it was recognized to be a cause of zoonotic malaria in humans. Due to
morphological similarities with P. malariae, the distinction fails under the microscope, thereby causing
misinterpretations in the epidemiological mapping, and the necessary interventions. This indicates that
molecular assays and diagnostic tools that implement genetic-based identification of the pathogen [119]
are needed, as also concluded by the study of Singh et al. [120]. Although the prevalence of P. knowlesi
is not high in areas of human settlements, but rather, in the wildlife areas where the host animals
live, factors like deforestation (or other ecological/environmental causes), human population increase,
hunting in the forest, and farming activities, may lead to the P. knowlesi changing its host preference
from the macaque monkey to human.
The ICT component comes into play with test results on domestic animals: it is known that the
Plasmodium malaria parasites that infect humans are not infective to livestock (referring to, e.g., sheep,
goats, swine, donkeys), therefore, there is no direct risk. However, domestic animals residing in close
proximity to people’s households may have an influence on local/district malaria prevalence that
is not straightforwardly advantageous or disadvantageous: on one hand, it may be that the vectors
are attracted by the animals instead of the humans, therefore, less people are bitten; or inversely, the
animals act as additional blood-feeding sources, increase the probability of vectors survival and, being
next to the human residences, increase the biting rate on the latter [121]. Results from mathematical
models predicting the influence of presence of livestock near people’s residences could be entered as
input parameters to the disease data management systems, in order to fine-tune the predictions, and
guide more efficient interventions, while providing more complete epidemiological perspectives.
Expanding the outreach of this review, even though it has been focused on malaria, it is widely
known that other tropical diseases co-exist, especially viral ones that are also vector-borne, for example
dengue, chikungunya, West Nile, Zika. The analysis that was conducted in the current review for the
convergence between human and vector diagnostics is also valid for the case of the aforementioned
vectors: molecular assay development compatibility for detection of the virus in humans and in
vectors; novel biochemistries in which the same extraction kit would be able to purify DNA from
parasite, and RNA from virus, no matter if it comes from human sample or mosquito homogenate.
Even though it may be unlikely that, especially for vector control, tests for malaria and arboviruses
would need to be performed simultaneously, still from the economics perspective, it is highly beneficial
for the suppliers and manufacturers to have a “one-size-fits-all” platform. Furthermore, it has to
be noted that malaria in the context of global health is not only related to diagnosis of humans and
mosquitoes (and animals), but also to treatment, as presented in Figure 4. Close interconnection
also with environmental features should be taken in consideration during global studies for malaria
prevalence, transmission, and elimination [122]. All these create a unifying umbrella, the One Health.
Bringing together the human and vector fields can be considered the first step (dashed line in Figure 4,
topics discussed in this review). However, there are plenty of other interconnections that could and
should be taken into consideration.
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